- Biological E. Ltd on Monday commissioned its manufacturing plant at the Genome Valley Special Economic Zone near here and unveiled its new Typhoid Conjugate Vaccine (TCV)
- Recently, BE received authorisation from the health regulatory authorities to license and market a new Typhoid Conjugate Vaccine
- The vaccine was developed in partnership with the GSK Vaccines Institute for Global Health, based in Siena (Italy), which first developed the asset and transferred it to BE in 2013
685 West Baltimore Street, Room 480
Baltimore, MD 21201-1509
Baltimore, MD 21201-1509
Washington, DC 20037
© 2018. Coalition Against Typhoid. All Rights Reserved.